Abstract: Disclosed are new dihydropteridinones of general formula (I) whereby the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropteridinones and their use as pharmaceutical compositions.

Abstract: An adjusting system of a motor vehicle for the adjustment of a closing part is disclosed. The system includes a first and second casing extending oblong in a length-wise direction. The second casing has a smaller cross section than the first casing and is arranged within the first casing to be adjustable in a length-wise direction. A spindle for the relative adjustment of a first casing to the second casing is included and arranged within either or both of the first and second casings. The system also includes an electromotor and a transmission connected with either or both of the spindle and second casing. In addition, at least one spring is arranged within either or both of the first and second casings and operates length-wise, such that one of the casings is attached on the side of the motor vehicle body and another of the casings is attached to the closing side.

Abstract: A driving unit especially adapted to adjusting devices for motor vehicles having an electric motor, a gear box and an electronic control device. At least one element of the electric motor, for example, at the driving shaft, the magnetic short-circuit or the motor side crankcase casing, additionally provides a gear box mechanical feature and/or a mechanical member, for example, a gear box side crankcase casing, provides an electric motor or electronic control device feature.

Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R5 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.

Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Abstract: Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R1 to R4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

Abstract: A process for detecting the operating state of a pump of a pump system, involves the steps of: detecting at least one pressure nd/or flow profile P(t) in the pump system, computing of at least one characteristic value Kkal from the pressure and/or flow profile P(t), comparing the computed characteristic value Kkal with at least one defined characteristic value Kvor or with a range bordered by the characteristic value Kvor, the defined characteristic value Kvor or the characteristic value range corresponding to the operating state of the pump of interest, and outputting the operating state determined by the comparison. With the process, the operating states of pumps, pump systems and hydraulic systems is determined by the computed characteristic value Kkal characterizing the pulsation of the pressure and/or flow profile P(t) in a computation time interval ?tB, the pulsation quotient being computed as the computed characteristic value Kkal.

Abstract: The present invention relates to new thiazolyl-dihydro-indazoles of general formula (I) wherein the groups R1, R2 and R3 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-indazoles and the use thereof as pharmaceutical compositions.

Abstract: Disclosed are compounds of general formula (I), wherein the groups A, R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

Abstract: Disclosed are compounds of general formula (I), wherein the groups R1, R2, Ra and Rb have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-cyclopentapyrazoles and the use thereof as pharmaceutical compositions.

Abstract: Presented are compounds represented by the following general formulas (I) and (II), for inhibiting cysteine protease legumain for modulating associated disease states in subjects

Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.

Abstract: Disclosed are 6-formyl-tetrahydropteridines of the formula (I) wherein the groups R1 to R6 have the meanings given in the claims and specification, the isomers thereof, methods of preparing these 6-formyl-tetrahydropteridines and their use as medicaments.

Abstract: The present invention comprises compounds of general formula (1) wherein A, X, Y, Z, Ra, Rb, Rc, R1, R2 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.

Abstract: A motor vehicle seat back structure comprising a backrest support frame which consists of a surface turned towards the seat user's back, a lordosis support which is arranged on the front part of the backrest support frame for supporting the user's back and an adjusting device for vertically adjusting the lordosis support position with respect to the extension plane of said backrest support frame. The adjusting device comprises at least one adjusting element operably connected to the lordosis support and at least one sliding element which is displaceable with respect to said adjusting element and interacts therewith in such a way that when the sliding element moves, the adjusting element is displaced with a directional component perpendicularly to the displacement direction of the sliding element and performs an action on said lordosis support in the direction.

Abstract: An application unit and a modem unit for mobile communication are provided. The application unit comprises at least one application that exchanges data traffic with at least one protocol stack, wherein said at least one protocol stack transfers data between at least one of the applications and at least one physical interface. The modem unit comprises a broadcast facility for setting up a wireless connection, and at least one transmission protocol stack for transferring data traffic between the at least one physical interface and the broadcast facility. The modem unit collects flow control information about the status of the wireless connection. The flow control information are packed into an IP packet which is sent via the physical interface to the application unit. The application unit uses the received flow control information to optimize the quality of service.

Abstract: The present invention relates to the use of dihydropteridinones of formula 1 wherein the groups X, R1, R2, R3, R4, R5, R6 and R7 have the meanings given in the claims and specification, for the preparation of a medicament for the treatment of respiratory diseases.

Abstract: The present invention relates to method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non-insulin dependent diabetes mellitus (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus the predi,betic state and/or obesity and to compositions for use in s ch method.

Abstract: The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV—like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1-36).

Abstract: The present invention discloses a method for therapeutically treating an animal, including a human, for psychosomatic, depressive and neuropsychiatric diseases, such as anxiety, depression, insomnia, schizophrenia, epilepsy, spasm and chronic pain. Administration of a suitable DP IV inhibitor causes the reduction of activity in the enzyme dipeptidyl peptidase (DP IV or CD 26) or of DP IV-like enzyme activity in the brain of mammals and leads as a causal consequence to a reduced degradation of the neuropeptide Y (NPY) and similar substrates by DP IV and DP IV-like enzymes. Such treatment will result in a reduction or delay in the decrease of the concentration of functionally active neuronal NPY (1–36).